- Anti- Inflammatory drugs
- Immunosuppressant
- PDE5 inhibitors
- Calcium channel blockers
- others
Scleroderma Treatment Market was valued at USD 5.2 Bn in 2022 and expected to grow at a CAGR of 7.2% during the forecast period 2023 to 2029. Scleroderma is an immune system state of the connective tissue portrayed by skin thickening, unconstrained scarring, vein infection, and differing degrees of irritation, related with an overactive invulnerable framework. Immune system ailments are diseases that happen when the body's tissues are assaulted by its own safe framework. Scleroderma is described by the development of scar tissue (fibrosis) in the skin. This prompts thickness and immovability of included skin. This may likewise happen in inside organs, for example, the kidney. The scleroderma treatment market is highly fragmented because of the many market players. These market players are progressively going up against each other in view of variables, for example, forceful evaluating and new signs. Market Players are taking endeavours to address the neglected medicinal needs by developing novel therapeutics. They are likewise concentrating on the improvement of medications in new course of organizations (ROAs, for example, topical patches). To enhance their market positions, the players in this market space additionally focusing on embracing systems, for example, M&A and distribution through partnerships. Stem cell transplants can furnish managed abatements in patients with extreme immune system infections, for example, lupus, rheumatoid joint inflammation, adolescent joint inflammation, and numerous sclerosis. The autologous platelet undeveloped cell transplants can altogether enhance the survival rate of patients experiencing scleroderma conditions
Global Scleroderma Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
7.2%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Scleroderma Treatment Market Dynamics
Expanding commonness of scleroderma and rising frequencies of hereditary transformations combined with radical changes in condition is the high effect rendering jumpers for scleroderma drugs market. As indicated by International reports from Japan and Britain, predominance of fundamental scleroderma is around 35 cases for every 1 million grown-ups. Ladies are four times more inclined to create fundamental scleroderma than men. Also, nearness of high neglected medicinal needs and the consequent acquaintance of new items providing food with these requirements are relied upon to serve scleroderma drugs market as future development opportunities.
North-America got significant share
Scleroderma Treatment Market Regional Analysis
Geographically scleroderma tretment market is segmented as Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe. North America dominates the scleroderma treatment market over the forecast period. Government research development programs and favourable reimbursement scenario combined with high market infiltration rates coupled to drive scleroderma drugs market. Besides, nearness of a broad number of clinical preliminaries went for upgrading adequacy and new item improvement in the district is relied upon to fuel future market development. Asia Pacific developed as the quickest developing region attributable to an expansive nearness of neglected patient needs and the ensuing ascent in utilization rates. Moreover, nearness of good government activities in Japan and Australia is relied upon to drive the scleroderma treatment market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The scleroderma tretment market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup's details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market
Global Scleroderma Treatment Market Segmentation
By Drug Class
By Indication
- Localized
- Systemic
By Distribution Channel
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
Frequently Asked Questions
The Scleroderma Treatment Market size was valued at USD 5.2 billion in 2022
The Scleroderma Treatment Market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
Asia Pacific is the fastest-growing for Scleroderma Treatment Market
| 1.Executive Summary |
| 2.Global Scleroderma Treatment Market Introduction |
| 2.1.Global Scleroderma Treatment Market - Taxonomy |
| 2.2.Global Scleroderma Treatment Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Indication |
| 2.2.3.Distribution Channel |
| 2.2.4.Region |
| 3.Global Scleroderma Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Scleroderma Treatment Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Scleroderma Treatment Market By Drug Class, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Anti- Inflammatory drugs |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Immunosuppressant |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. PDE5 inhibitors |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Calcium channel blockers |
| 5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. others |
| 5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Scleroderma Treatment Market By Indication, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Localized |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Systemic |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Scleroderma Treatment Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. Retail Pharmacies |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Online Pharmacies |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Hospital Pharmacies |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Scleroderma Treatment Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Scleroderma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. Drug Class Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Anti- Inflammatory drugs |
| 9.1.2.Immunosuppressant |
| 9.1.3.PDE5 inhibitors |
| 9.1.4.Calcium channel blockers |
| 9.1.5.others |
| 9.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Localized |
| 9.2.2.Systemic |
| 9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Retail Pharmacies |
| 9.3.2.Online Pharmacies |
| 9.3.3.Hospital Pharmacies |
| 9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Scleroderma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Anti- Inflammatory drugs |
| 10.1.2.Immunosuppressant |
| 10.1.3.PDE5 inhibitors |
| 10.1.4.Calcium channel blockers |
| 10.1.5.others |
| 10.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Localized |
| 10.2.2.Systemic |
| 10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Retail Pharmacies |
| 10.3.2.Online Pharmacies |
| 10.3.3.Hospital Pharmacies |
| 10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Scleroderma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Anti- Inflammatory drugs |
| 11.1.2.Immunosuppressant |
| 11.1.3.PDE5 inhibitors |
| 11.1.4.Calcium channel blockers |
| 11.1.5.others |
| 11.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Localized |
| 11.2.2.Systemic |
| 11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Retail Pharmacies |
| 11.3.2.Online Pharmacies |
| 11.3.3.Hospital Pharmacies |
| 11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Scleroderma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Anti- Inflammatory drugs |
| 12.1.2.Immunosuppressant |
| 12.1.3.PDE5 inhibitors |
| 12.1.4.Calcium channel blockers |
| 12.1.5.others |
| 12.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Localized |
| 12.2.2.Systemic |
| 12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Retail Pharmacies |
| 12.3.2.Online Pharmacies |
| 12.3.3.Hospital Pharmacies |
| 12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Scleroderma Treatment Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Anti- Inflammatory drugs |
| 13.1.2.Immunosuppressant |
| 13.1.3.PDE5 inhibitors |
| 13.1.4.Calcium channel blockers |
| 13.1.5.others |
| 13.2. Indication Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Localized |
| 13.2.2.Systemic |
| 13.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Retail Pharmacies |
| 13.3.2.Online Pharmacies |
| 13.3.3.Hospital Pharmacies |
| 13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Bristol Myers Squibb (U.S.) |
| 14.2.2.Johnson & Johnson Services, Inc. (U.S.) |
| 14.2.3.Eli Lilly and Company (U.S.) |
| 14.2.4.Pfizer, Inc. (U.S.) |
| 14.2.5.Abbott Laboratories (U.S.) |
| 14.2.6.GlaxoSmithKline plc (U.K.) |
| 14.2.7.Novartis AG (Switzerland) |
| 14.2.8.Sanofi S.A. (France) |
| 14.2.9.Astellas Pharma, Inc. (Japan) |
| 14.2.10.Bayer AG (Germany) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Bristol Myers Squibb (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Pfizer, Inc. (U.S.)
- Abbott Laboratories (U.S.)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Sanofi S.A. (France)
- Astellas Pharma, Inc. (Japan)
- Bayer AG (Germany)